Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.
S Sud, C O'Callaghan, C Jonker, C Karapetis, T Price, N Tebbutt, J Shapiro, G Van Hazel, N Pavlakis, P Gibbs, M Jeffrey, L Siu, S Gill, R Wong, D Jonker, D Tu, R Goodwin
Curr Oncol | Published : 2018
Background: Adrenergic receptor stimulation is involved in the development of hypertension (htn) and has been implicated in cancer progression and dissemination of metastases in various tumours, including colon cancer. Adrenergic antagonists such as beta-blockers (bbs) demonstrate inhibition of invasion and migration in colon cancer cell lines and have been associated with decreased mortality in colorectal cancer (crc). We examined the association of baseline htn and bb use with overall (os) and progression-free survival (pfs) in patients with pretreated, chemotherapy refractory, metastatic crc (mcrc). We also examined baseline htn as a predictor of cetuximab efficacy. Methods: Using data fr..View full abstract